このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Zhejiang Orient Gene Biotech マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Xiaoliang Fang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	7.5yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	7.5yrs

経営陣の近況

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

CEO（最高経営責任者

Xiaoliang Fang (67 yo)

7.5yrs

在職期間

CN¥1,152,900

報酬

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.

取締役

名称	ポジション	在職期間	報酬	所有権
Xiaoliang Fang	GM & Director	7.5yrs	CN¥1.15m	データなし
Xiaoping Han	Independent Director	7.5yrs	CN¥100.00k	データなし
Jianqiu Fang	Chairman	7.5yrs	CN¥1.25m	データなし
Wei Lin	Independent Director	7.5yrs	CN¥100.00k	データなし
Haiying Feng	Chairman of the Board of Supervisors	7.5yrs	データなし	0.13% CN¥ 4.8m

7.5yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: 688298の取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Zhejiang Orient Gene Biotech マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Recent updates

Zhejiang Orient Gene Biotech Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.43 loss per share (vs CN¥0.41 profit in 2Q 2023)

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Zhejiang Orient Gene Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14